Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis

Pathology. 1996 Aug;28(3):255-8. doi: 10.1080/00313029600169104.

Abstract

The apparent coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis in the same patient raises unresolved problems for nosology and therapy. These are exemplified by a 45-year-old Japanese woman with overlapping clinical, serological and histological features of autoimmune cholangitis and autoimmune hepatitis. The classical serological test for PBC, antimitochondrial antibody (AMA) by immunofluorescence, was atypical. By immunoblotting there was reactivity with one of the enzymes of the 2-oxo-acid dehydrogenase complex (2-OADC) family, now recognized as autoantigens responsible for AMA reactivity. Also there was reactivity by immunofluorescence for antinuclear antibodies (ANA), one showing the typical speckled pattern of anti-Sp-100 and the other the peripheral pattern of antinuclear membrane antibody, both with titres > 10(6). There was also a positive result to the lupus erythematosus (LE) cell test. Treatment with ursodeoxycholic acid was beneficial. Thus while the clinical presentation suggested the overlapping syndrome of autoimmune hepatitis and PBC, PBC eventually proved to be the likely diagnosis. We suggest that apparent cases of overlapping PBC-autoimmune cholangitis-hepatitis syndromes, after detailed testing, will mostly align with PBC.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antinuclear / metabolism
  • Autoimmune Diseases / metabolism
  • Autoimmune Diseases / pathology*
  • Cholangitis / drug therapy
  • Cholangitis / metabolism
  • Cholangitis / pathology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fluorescent Antibody Technique
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Immunoblotting
  • Liver Cirrhosis, Biliary / drug therapy
  • Liver Cirrhosis, Biliary / metabolism
  • Liver Cirrhosis, Biliary / pathology*
  • Middle Aged
  • Pyruvate Dehydrogenase Complex / metabolism
  • Syndrome
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Antibodies, Antinuclear
  • Gastrointestinal Agents
  • Pyruvate Dehydrogenase Complex
  • Ursodeoxycholic Acid